Cybin Inc. (HELP)
NASDAQ: HELP · Real-Time Price · USD
5.25
-0.39 (-6.91%)
At close: Mar 6, 2026, 4:00 PM EST
5.30
+0.05 (0.95%)
After-hours: Mar 6, 2026, 7:49 PM EST
Cybin Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
50
Market Cap
262.69M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Coherus Oncology | 277.73M |
| Cellectis | 82.55M |
| Fennec Pharmaceuticals | 38.79M |
| OmniAb | 18.67M |
| Prelude Therapeutics | 10.50M |
| Ovid Therapeutics | 6.61M |
| AC Immune | 5.48M |
| Abeona Therapeutics | 400.00K |
HELP News
- 16 hours ago - Cybin Inc. (HELP) Discusses Phase II Results for HLP004 in Generalized Anxiety Disorder Prepared Remarks Transcript - Seeking Alpha
- 1 day ago - Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints - Benzinga
- 1 day ago - Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder - GlobeNewsWire
- 10 days ago - HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience - Seeking Alpha
- 10 days ago - Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee - GlobeNewsWire
- 17 days ago - Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder - GlobeNewsWire
- 21 days ago - HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - Cybin Initiates At-The-Market Equity Program of up to US$100 Million - Business Wire